ARVNArvinas Inc
−2.1% today · −35.9% over a year
No score: too little data.
Trend: among the weakest. No dividend.
Arvinas Inc (ARVN) belongs to the Health care sector and is listed on Nasdaq; country: United States. Its market value is about €376M. Over the past 12 months the price changed by −35.9%, with an annualised volatility of 56% and a largest fall of 54%. Hard red flags in our rules-based screen: Heavy dilution.
Smart Score
How it is scored →Not scored: not enough data for a fair comparison.
Factor scores
Percentiles within the peer group (100 = the best of its peers); dividend safety in points.
Main drivers
- Share issuance (1 y)supports the score · better than 99% of peers
- 12-month trend (ex last month)weighs on the score · better than 13% of peers
- Accrualsweighs on the score · better than 3% of peers
Red flags and notes
- Serious warning. Share count growing more than 10 % a year over three years. More in the glossary → Share count growing more than 10 % a year over three years.
- Caution. Negative free cash flow in at least two of the last three years. More in the glossary → Negative free cash flow in at least two of the last three years.
- Caution. Accruals or the Beneish M-score are in the watch zone. More in the glossary → Accruals or the Beneish M-score are in the watch zone.
- Sources disagree Dividend or fundamental sources disagree beyond tolerance.
Our sources disagree or are incomplete for this instrument.
Price chart
Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.
Key metrics
Valuation
- P/B
- 0.8
- P/S
- 1.5
- Free-cash-flow yield
- −49.7%
- Market cap (EUR)
- €376M
Profitability and debt
- Return on equity
- −1.8%
- Return on invested capital
- −7.5%
Dividends
- Dividend yield
- 0.00%
- Years without a lower dividend
- 0
Returns and risk
- 1 day
- −2.1%
- 1 month
- −12.3%
- 1 year
- −35.9%
- Volatility, 1 yr
- 56.4%
- Max drawdown, 1 yr
- −53.7%
- Beta
- 1.30
Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.
Similar companies
Same sector and region, closest in market value.
| ALTAltimmune | 1/10 | 0.0% | −47.2% |
|---|---|---|---|
| EDITEditas Medicine Inc | 1/10 | 0.0% | −4.5% |
| ALLOAllogene Therapeutics Inc | —/10 | 0.0% | −1.0% |
| EMBCEmbecta | 3/10 | 5.2% | −52.5% |
| RGNXREGENXBIO Inc | —/10 | 0.0% | −31.8% |
| AVIRAtea Pharmaceuticals | —/10 | 0.0% | 32.6% |
| ALECAlector | 1/10 | 0.0% | 76.2% |
| EVHEvolent Health Inc | 1/10 | 0.0% | −23.7% |
News and filings
- ARVINAS, INC.: 10-Q — Quarterly report for the period ending 30 Sep 2026
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 3 Nov 2026
- ARVINAS, INC.: 8-K — Results of operations; Regulation FD disclosure
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 3 Nov 2026
What the marks mean
- FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
- Media reportA headline from a named media outlet. We link to it and do not check it.
- RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.
Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.
Score changes in the last 12 months
Every published rating and change, logged when it was published (EU Market Abuse Regulation).
Show the log: 1 entry
| Date | Event | Balanced | Growth · Income | Warnings | Price at publication |
|---|---|---|---|---|---|
| First rating | —/10 | — · — | Available with Invest Pro |
Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.
Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.